• Positive CHMP opinion follows FDA approval for Boehringer Ingelheim’s frontrunner oncology compound
• The largest global Phase III registration trial, LUX-Lung 3, demonstrated that patients with EGFR mutation positive lung cancer benefited from afatinib treatment versus standard chemotherapy
INGELHEIM, Germany I July 26, 2013 I Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for afatinib – which has been submitted under the European Union brand name GIOTRIF®*. Afatinib is the first irreversible ErbB Family Blocker for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
“Boehringer Ingelheim welcomes the decision by the CHMP which follows the recent FDA approval of afatinib. We look forward to making afatinib available soon to patients with EGFR mutation positive lung cancer in Europe,” said Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “Afatinib irreversibly blocks EGFR and other relevant members of the ErbB Family and has demonstrated a meaningful therapeutic benefit in clinical trials.”
The prevalence of tumours harbouring EGFR mutations is between 10-15% in Caucasian and 40% in Asian NSCLC patients.1 In clinical trials, afatinib has been shown to offer patients with this type of lung cancer a significant delay in tumour progression, coupled with improvements in their lung cancer related symptoms and quality of life.2,3 Therefore, testing for mutations in EGFR is a crucial step in the treatment-decision pathway, and is strongly recommended by many international oncology organisations. This enables healthcare professionals to make informed treatment decisions and patients to receive the right targeted therapy from the start.
“Targeted therapies offer a personalised approach to lung cancer treatment, from which patients can hugely benefit”, commented Dr. Sanjay Popat, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London and clinical investigator in the LUX-Lung 3 trial. “Today’s recommendation for approval of afatinib by the CHMP brings us even closer to providing patients in Europe with advanced NSCLC, the prospect of a targeted treatment option, which has demonstrated consistent and superior efficacy compared with standard chemotherapy across large scale clinical trials.”
The CHMP’s positive opinion for afatinib is based on data from the pivotal LUX-Lung 3 trial, the largest global Phase III trial in patients with EGFR mutation positive lung cancer, comparing afatinib to chemotherapy with pemetrexed/cisplatin. Data from LUX-Lung 3 has shown that patients taking afatinib as a first-line treatment lived for almost one year without their tumour growing again (median progression-free survival (PFS) of 11.1 months) versus just over half a year (PFS of 6.9 months) for those treated with pemetrexed/ cisplatin. Of note, NSCLC patients with tumours harbouring the two most common EGFR mutations (del19 or L858R, accounting for 90% of all EGFR mutations) taking afatinib lived for well over a year without tumour progression (PFS of 13.6 months) versus just over half a year (PFS of 6.9 months) for those in the comparator arm.2
The delay in disease progression for afatinib demonstrated in clinical trials was associated with better control of life-restricting disease-related symptoms. More patients taking afatinib experienced improvement of symptoms such as dyspnoea (shortness of breath), cough and chest pain, as measured by standard lung cancer questionnaires. Afatinib also delayed the worsening of these symptoms.3
There was a low discontinuation rate associated with treatment-related adverse events in the LUX-Lung 3 trial (8% discontinuation rate for afatinib; 12% for chemotherapy). The most common grade 3 drug-related adverse events observed in the afatinib treatment arm were diarrhoea (14%), rash (16%), and inflammation of the nail bed (paronychia) (11%). One percent of patients in the afatinib arm discontinued due to drug-related diarrhoea.2 The most common drug-related grade 3 adverse events observed in the chemotherapy arm (pemetrexed/cisplatin) were neutropenia (15%), fatigue (13%), and leucopenia (8%).
Afatinib is approved in the U.S. under the U.S. brand name GILOTRIF™ and has been submitted to regulatory bodies in Asia and worldwide for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations. Regulatory reviews by health authorities in the EU, Asia and other countries are ongoing.
About Afatinib
Afatinib is approved by the U.S. FDA for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Afatinib is an irreversible ErbB Family Blocker which irreversibly blocks EGFR (ErbB1) as well as the other relevant members of the ErbB Family that are known to play a critical role in the growth and spread of the most pervasive cancers and cancers associated with high mortality. The covalent and, therefore, irreversible binding of afatinib is unlike other compounds which are reversible in that it provides a sustained, selective, and complete ErbB Family Blockade, and therefore may lead to a distinct therapeutic benefit.4,5
Afatinib is currently in Phase III clinical development in NSCLC and head & neck cancer.
About Lung Cancer
Lung cancer is the biggest cancer killer in the world with incidence rates higher in men than in women, it accounts for 1.6 million new cancer cases annually. Because of its poor prognosis, 1.38 million deaths each year are attributable to lung cancer. Overall, lung cancer is the cause of 18% of all cancer deaths.6 Approximately 13% of all new cases of cancer are lung cancers7 and smoking is attributed as the main cause.
Early testing for tumour EGFR mutation status is critical in improving patient outcomes. Between 10-15% of Caucasian and 40% of Asian NSCLC patients have tumours harbouring EGFR mutations, which in 90% of cases are one of the two most common EGFR mutations (Del19 or L858R).1
About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centres, Boehringer Ingelheim’s commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumours and haematological cancers.
The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. Volasertibi is the most advanced pipeline compound for haematological cancers. The pipeline for haematological cancers also includes two new biological entities (NBEs) using an immunotherapeutic approach: BI 836858 is an anti-CD33 antibody targeting AML and BI 836826 is an anti-CD37 antibody targeting chronic lymphocytic leukaemia (CLL) and B-cell non-Hodgkin’s lymphoma (B-NHL).
Boehringer Ingelheim’s oncology pipeline is evolving and demonstrates the company’s continued commitment to advance the disease area.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information please visit: www.newshome.com
* Afatinib’s anticipated brand name for the European Union is GIOTRIF®. In the U.S., afatinib is approved under the U.S. brand name GILOTRIF™. Regulatory reviews by health authorities in the EU, Asia and other countries are ongoing.
i Volasertib is an investigational compound and is not yet approved. It’s safety and efficacy have not yet been fully established.
References
1 Jang TW et al. 2009. EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung. The Korean Journal of Internal Medicine, March; 24(1), pp.48–54.
2 Yang JC, Shuler M, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012;30(18,Suppl):abstract LBA 7500.
3 Sequist LV et al. LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations. ESMO 2012 Congress. Abstract no: 1229PD.
4 Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50.
5 Reid A, Vidal L, Shaw H, do Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-9.
6 Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
7 Cancer Research UK. UK lung cancer incidence. CancerStats – Key Facts 2009. [Online] Available at: http://info.cancerresearchuk.org/cancerstats/types/lung/incidence/ [Last Accessed July 2013].
SOURCE: Boehringer Ingelheim
Post Views: 201
• Positive CHMP opinion follows FDA approval for Boehringer Ingelheim’s frontrunner oncology compound
• The largest global Phase III registration trial, LUX-Lung 3, demonstrated that patients with EGFR mutation positive lung cancer benefited from afatinib treatment versus standard chemotherapy
INGELHEIM, Germany I July 26, 2013 I Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for afatinib – which has been submitted under the European Union brand name GIOTRIF®*. Afatinib is the first irreversible ErbB Family Blocker for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
“Boehringer Ingelheim welcomes the decision by the CHMP which follows the recent FDA approval of afatinib. We look forward to making afatinib available soon to patients with EGFR mutation positive lung cancer in Europe,” said Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “Afatinib irreversibly blocks EGFR and other relevant members of the ErbB Family and has demonstrated a meaningful therapeutic benefit in clinical trials.”
The prevalence of tumours harbouring EGFR mutations is between 10-15% in Caucasian and 40% in Asian NSCLC patients.1 In clinical trials, afatinib has been shown to offer patients with this type of lung cancer a significant delay in tumour progression, coupled with improvements in their lung cancer related symptoms and quality of life.2,3 Therefore, testing for mutations in EGFR is a crucial step in the treatment-decision pathway, and is strongly recommended by many international oncology organisations. This enables healthcare professionals to make informed treatment decisions and patients to receive the right targeted therapy from the start.
“Targeted therapies offer a personalised approach to lung cancer treatment, from which patients can hugely benefit”, commented Dr. Sanjay Popat, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London and clinical investigator in the LUX-Lung 3 trial. “Today’s recommendation for approval of afatinib by the CHMP brings us even closer to providing patients in Europe with advanced NSCLC, the prospect of a targeted treatment option, which has demonstrated consistent and superior efficacy compared with standard chemotherapy across large scale clinical trials.”
The CHMP’s positive opinion for afatinib is based on data from the pivotal LUX-Lung 3 trial, the largest global Phase III trial in patients with EGFR mutation positive lung cancer, comparing afatinib to chemotherapy with pemetrexed/cisplatin. Data from LUX-Lung 3 has shown that patients taking afatinib as a first-line treatment lived for almost one year without their tumour growing again (median progression-free survival (PFS) of 11.1 months) versus just over half a year (PFS of 6.9 months) for those treated with pemetrexed/ cisplatin. Of note, NSCLC patients with tumours harbouring the two most common EGFR mutations (del19 or L858R, accounting for 90% of all EGFR mutations) taking afatinib lived for well over a year without tumour progression (PFS of 13.6 months) versus just over half a year (PFS of 6.9 months) for those in the comparator arm.2
The delay in disease progression for afatinib demonstrated in clinical trials was associated with better control of life-restricting disease-related symptoms. More patients taking afatinib experienced improvement of symptoms such as dyspnoea (shortness of breath), cough and chest pain, as measured by standard lung cancer questionnaires. Afatinib also delayed the worsening of these symptoms.3
There was a low discontinuation rate associated with treatment-related adverse events in the LUX-Lung 3 trial (8% discontinuation rate for afatinib; 12% for chemotherapy). The most common grade 3 drug-related adverse events observed in the afatinib treatment arm were diarrhoea (14%), rash (16%), and inflammation of the nail bed (paronychia) (11%). One percent of patients in the afatinib arm discontinued due to drug-related diarrhoea.2 The most common drug-related grade 3 adverse events observed in the chemotherapy arm (pemetrexed/cisplatin) were neutropenia (15%), fatigue (13%), and leucopenia (8%).
Afatinib is approved in the U.S. under the U.S. brand name GILOTRIF™ and has been submitted to regulatory bodies in Asia and worldwide for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations. Regulatory reviews by health authorities in the EU, Asia and other countries are ongoing.
About Afatinib
Afatinib is approved by the U.S. FDA for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Afatinib is an irreversible ErbB Family Blocker which irreversibly blocks EGFR (ErbB1) as well as the other relevant members of the ErbB Family that are known to play a critical role in the growth and spread of the most pervasive cancers and cancers associated with high mortality. The covalent and, therefore, irreversible binding of afatinib is unlike other compounds which are reversible in that it provides a sustained, selective, and complete ErbB Family Blockade, and therefore may lead to a distinct therapeutic benefit.4,5
Afatinib is currently in Phase III clinical development in NSCLC and head & neck cancer.
About Lung Cancer
Lung cancer is the biggest cancer killer in the world with incidence rates higher in men than in women, it accounts for 1.6 million new cancer cases annually. Because of its poor prognosis, 1.38 million deaths each year are attributable to lung cancer. Overall, lung cancer is the cause of 18% of all cancer deaths.6 Approximately 13% of all new cases of cancer are lung cancers7 and smoking is attributed as the main cause.
Early testing for tumour EGFR mutation status is critical in improving patient outcomes. Between 10-15% of Caucasian and 40% of Asian NSCLC patients have tumours harbouring EGFR mutations, which in 90% of cases are one of the two most common EGFR mutations (Del19 or L858R).1
About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research programme to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centres, Boehringer Ingelheim’s commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumours and haematological cancers.
The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. Volasertibi is the most advanced pipeline compound for haematological cancers. The pipeline for haematological cancers also includes two new biological entities (NBEs) using an immunotherapeutic approach: BI 836858 is an anti-CD33 antibody targeting AML and BI 836826 is an anti-CD37 antibody targeting chronic lymphocytic leukaemia (CLL) and B-cell non-Hodgkin’s lymphoma (B-NHL).
Boehringer Ingelheim’s oncology pipeline is evolving and demonstrates the company’s continued commitment to advance the disease area.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information please visit: www.newshome.com
* Afatinib’s anticipated brand name for the European Union is GIOTRIF®. In the U.S., afatinib is approved under the U.S. brand name GILOTRIF™. Regulatory reviews by health authorities in the EU, Asia and other countries are ongoing.
i Volasertib is an investigational compound and is not yet approved. It’s safety and efficacy have not yet been fully established.
References
1 Jang TW et al. 2009. EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung. The Korean Journal of Internal Medicine, March; 24(1), pp.48–54.
2 Yang JC, Shuler M, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012;30(18,Suppl):abstract LBA 7500.
3 Sequist LV et al. LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations. ESMO 2012 Congress. Abstract no: 1229PD.
4 Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50.
5 Reid A, Vidal L, Shaw H, do Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-9.
6 Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
7 Cancer Research UK. UK lung cancer incidence. CancerStats – Key Facts 2009. [Online] Available at: http://info.cancerresearchuk.org/cancerstats/types/lung/incidence/ [Last Accessed July 2013].
SOURCE: Boehringer Ingelheim
Post Views: 201
